Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 530687, 5 pages
Research Article

Strontium Chloride: Can It Be a New Treatment Option for Ulcerative Colitis?

1Gastroenterology Clinic, Ataturk Training and Research Hospital, 35965 Izmir, Turkey
2Department of Gastroenterology, Faculty of Medicine, Cumhuriyet University, 58140 Sivas, Turkey
3Cumhuriyet Universitesi Hastanesi, Gastroenteroloji B.D., 58140 Sivas, Turkey
4Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Cumhuriyet University, 58140 Sivas, Turkey
5Department of Pathology, Faculty of Veterinary Medicine, Cumhuriyet University, 58140 Sivas, Turkey
6Gastroenterology Clinic, Anadolu Hospital, 58070 Sivas, Turkey
7Department of Dermatology, Faculty of Medicine, Cumhuriyet University, 58140 Sivas, Turkey

Received 26 February 2014; Revised 11 May 2014; Accepted 20 May 2014; Published 18 June 2014

Academic Editor: Guang-Yin Xu

Copyright © 2014 Firdevs Topal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background/Aims. Patients with ulcerative colitis still need effective therapy without major side effects. It has been found that strontium can suppress NFκB activation induced by TNF-α. This opens a gate to a new anti-TNF agent which is cheap and can be given orally. We for the first time aimed to investigate the effect of strontium chloride (SrCl2) on inflammation in experimental colitis. Methods. Thirty female Wistar albino rats were divided into 5 groups each containing 6 rats. The rats in groups 1 and 2 served as the healthy control and colitis group, respectively. The rats in groups 3, 4, and 5 had colitis and received 40 mg/kg SrCl2, 160 mg/kg SrCl2, and 1 mg/kg prednisolone by oral gavage, respectively. The rats were sacrificed for histological evaluation and determination of serum neopterin, TNF-α, and IFN-γ levels. Results. The neopterin, TNF-α and IFNγ levels of group 2 was significantly higher than the other groups. The neopterin, TNF-α, and IFN-γ levels of controls and other treatment groups were comparable. There were a significant difference in macroscopic and microscopic healing between group 2 and other groups histologically. But there was not a significant difference within treatment receiving groups. Conclusion. SrCl2 had comparable therapeutic efficiency with prednisolone.